MindWalk secures $30M debt facility to fund biologics — without issuing a share
What's the deal? MindWalk HoldingsDealroom has a profile for this one. Try Dealroom → (NASDAQ: HYFT), a bio-native AI company, has secured a binding commitment for a senior unsecured revolving credit facility of up to $30 million from Sanabil (Cayman)Dealroom has a profile for this one. Try Dealroom →. The funds will support MindWalkDealroom has a profile for this one. Try Dealroom →'s biologics programs, commercial expansion, working capital, and general corporate purposes.
The terms: The facility carries a fixed 7.00% annual interest rate, accruing only on amounts drawn, and runs an initial 36-month term, extendable by 12 months. It includes no financial maintenance covenants, no warrants, no equity conversion feature, and requires no pledge of MindWalk's assets.
MindWalk has no obligation to borrow and can repay drawn amounts without penalty. A one-time 1.00% opening fee applies, with no unused line fee. The two parties aim to close a definitive agreement within 60 days.
Why debt? Chief executive officer Jennifer Bath said MindWalk chose debt to avoid diluting shareholders. "We were not prepared to raise capital of this size in equity at the current share price, and we did not have to," she said.
She added that Sanabil "took no warrants, no conversion feature, and no security over any asset we own, so the full benefit of executing our plan stays with the shareholders who own it today."
What's the endgame? MindWalk builds what it calls BioIntelligence infrastructure for life sciences AI, combining data, models, and wet lab capabilities. Its core HYFT Technology spans 660 million patterns and 25 billion relationships, refined over 20 years, and underpins its ReefIQ data substrate and LensAI reasoning layer for drug target discovery and candidate diligence.
The signal: Opting for non-dilutive debt over equity is a growing choice for public companies wary of raising at depressed share prices. For MindWalk, the covenant-light structure buys funding for its biologics and commercial push while keeping upside with existing holders — a bet that its infrastructure will compound in value before repayment comes due.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
